Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. Its product candidate vonoprazan is an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Phathom Pharmaceuticals excels in Q4 with strong VOQUEZNA demand

Phathom Pharmaceuticals' Q4 2023 showcased strong financial performance and market acceptance of VOQUEZNA. The company's strategic focus on commercial expansion and physician engagement bodes well for future growth. Challenges include sustaining momentum, navigating competition, and managing expenses effectively.

Phathom Pharmaceuticals excels in Q1 with VOQUEZNA launch success

Phathom Pharmaceuticals demonstrated strong commercial progress with the successful launch of VOQUEZNA, driving revenue growth and expanding market access. Despite challenges in balancing expenses, the company's focus on label expansion and new trials presents significant growth opportunities. Overall, Phathom Pharmaceuticals is well-positioned for future success in the GI market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 3:15 p.m. GMT (10:15 a.m. ET).

Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

FLORHAM PARK, N.J., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 3:30 p.m. ET on Tuesday, September 15, 2020.

Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference

FLORHAM PARK, N.J., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2020.

Phathom Pharmaceuticals Reports Second Quarter 2020 Results

FLORHAM PARK, N.J., July  13, 2020  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Branning as Chief Financial Officer.  Interim CFO, David Socks, will continue with the company as a strategic advisor and remain a member of the Board of Directors.

Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer

First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pause Announced in March First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pause Announced in March

Phathom Pharmaceuticals Provides Clinical Trial Status Update

FLORHAM PARK, N.J., May  12, 2020  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2020.   

Phathom Pharmaceuticals Reports First Quarter 2020 Results

Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020

News for Phathom Pharmaceuticals Stock (PHAT)